NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big Rock Partners Acquisition Corp. and went public, changing its name in the process. The company develops Zyesami, a synthetic form […]
COVID-19
BD to build $200M facility in Spain for pre-filled drug delivery device manufacturing
BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up to 600 jobs by 2030, according to a news release. In December, BD announced its plan to invest […]
Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine
Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and […]
Diomics, Bonne Santé Group enter strategic alliance
Diomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products. San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address […]
Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]
NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19
NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]
Baxter to make Moderna COVID-19 vaccine in US
Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind. The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021. “We have seen a remarkable demonstration of scientific and health care expertise in […]
Intranasal COVID-19 vaccines could be on the horizon
All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID intranasal vaccine in 180 adult volunteers. Bharat Biotech […]
Pneumagen touts non-human results for intranasal drug treatment for COVID-19
Pneumagen announced today that study results show the effectiveness of its Neumifil intranasal drug in treating COVID-19. St. Andrews, Scotland-based Pneumagen’s Neumafil, a viral intranasal drug for protection against respiratory tract infections (RTIs), was used on a hamster model of COVID-19 infection and displayed effectiveness as it significantly reduced clinical signs and weight loss in […]
Why COVID-19 could drive a surge in diabetes
Diabetes was already an epidemic before the novel coronavirus struck. But some researchers now suspect that COVID-19 can trigger the condition. Approximately 14% of patients with severe COVID-19 develop the disease, according to a meta-analysis recently published in the journal Diabetes, Obesity and Metabolism. To arrive at that thesis, the researchers analyzed eight studies. Half of […]
